Sign Up Today and Learn More About Abridge Stock
Invest in or calculate the value of your shares in Abridge or other pre-IPO companies through EquityZen's platform.
Abridge Stock (ABRI)
Abridge is a medical conversation AI startup that structures and summarizes medical conversations for doctors and patients.
About Abridge Stock
Founded
2018
Headquarters
Pittsburgh, PA, US
Industries
Software, Data and Analytics, Science and Engineering
Abridge develops generative AI technology designed to automate clinical documentation by recording and summarizing medical conversations directly into Electronic Medical Records (EMRs). The company aims to reduce administrative burdens for healthcare providers, thereby allowing clinicians to focus primarily on patient care.
Abridge Press Mentions
Stay in the know about the latest news on Abridge
JPM: Abridge, Availity integrate conversational AI into prior authorization workflows
mobihealthnews • Jan 16, 2026
Abridge partners with Availity for AI-powered prior authorizations
techtarget • Jan 16, 2026
Abridge and Availity Collaborate to Redefine Payer-Provider Synergy at the Point of Conversation
businesswire • Jan 13, 2026
The Revenue Cycle Needs Surgery, Not Band-Aids
medcitynews • Jan 07, 2026
Northwell Health gains DOH approval for new pancreas transplant programme
hospitalmanagement • Dec 24, 2025
Abridge Management
Leadership team at Abridge
Co-Founder, CEO
Shivdev Rao
COO
Julia Chou Chapin
Join now and verify your accreditation status to gain access to:
- Abridge Current Valuation
- Abridge Stock Price
- Abridge Management
- Available deals in Abridge and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Abridge Cap Table and Funding History by Share Class and Liquidity Preferences
- Abridge Revenue and Financials
- Abridge Highlights
- Abridge Business Model
- Abridge Risk Factors
- Abridge Research Report from SACRA Research
Abridge Key Facts
- Substantial Capitalization and Valuation Growth: In June 2025, Abridge secured $300 million in Series E funding led by Andreessen Horowitz (a16z), effectively doubling its valuation to $5.3 billion in just four months. This capital infusion follows a period of hyper-growth where the company reportedly reached $117 million in contracted Annual Recurring Revenue (ARR) as of Q1 2025. This financial strength provides a significant competitive moat against smaller startups and allows for aggressive R&D into "upstream" healthcare workflows.
- Enterprise-Scale Market Penetration: Abridge has moved beyond pilot phases to full-scale enterprise mandates, now serving over 200 large-scale health systems. Notable 2025 expansions include UPMC, which is scaling the platform to 12,000 clinicians by 2026, and Kaiser Permanente, which launched the industry's largest generative AI project using Abridge across 40 hospitals. These deep integrations, particularly within Epic’s EHR environment, position Abridge as the default standard for high-volume academic and integrated delivery networks (IDNs).
- Expansion into Revenue Cycle and Payer Ecosystems: Through the launch of its Contextual Reasoning Engine, Abridge has successfully diversified its product utility to include real-time revenue cycle intelligence and prior authorization. A landmark August 2025 partnership with Highmark Health introduced a first-of-its-kind solution that facilitates real-time prior authorization during patient visits, reducing approval timelines from weeks to minutes. This strategic shift transforms the tool from a clinician burnout solution into a critical financial performance lever for health systems.
- Platform Capture and "Co-opetition" Risk from Dominant EHR Ecosystems: Intensifying competition from Epic and other ambient AI vendors is emerging as a material strategic threat. Epic, a former investor and key distribution partner, has announced its own Microsoft‑powered AI note‑generation tools that directly overlap with Abridge’s core scribe offering, raising the risk that Epic will steer a portion of its 40%+ U.S. hospital EHR base toward in‑house solutions and away from Abridge over time. Business Insider and STAT note that Abridge must now lock in existing Epic customers while expanding to other EHR ecosystems to avoid revenue concentration and potential displacement risk.
- Regulatory Compliance and "Agentic" Shift: The phased enforcement of the EU AI Act beginning in 2026 classifies many clinical AI systems as high-risk, requiring "hardware-grade" quality systems and rigorous auditability. As Abridge shifts from simple transcription to "agentic" AI it faces a steeper integration tax and higher compliance costs. Furthermore, new U.S. federal guidance under the GENIUS Act (expected by July 2026) will mandate stricter documentation of training data lineage and model behavior, potentially slowing Abridge's rapid feature deployment cycle.
- Macroeconomic Headwinds and Market Consolidation: The healthcare AI sector is entering a projected "collapse of point solutions" in 2026. Health systems, facing tighter margins due to the One Big Beautiful Bill Act (OBBBA) and expiring ACA subsidies, are increasingly consolidating their tech stacks. This creates a "maturity wall" where Abridge must prove hard ROI rather than just "soft" metrics like time saved. Competitively, the risk of "platform capture" by EHR giants like Epic, who may eventually develop native, low-cost alternatives, remains a primary long-term threat to Abridge’s premium pricing model.
Trading Abridge Stock
How to invest in Abridge stock?
Accredited investors can buy pre-IPO stock in companies like Abridge through EquityZen funds. These investments are made available by existing Abridge shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Abridge stock?
Shareholders can sell their Abridge stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
